ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Arena, Eisai Diet Drug Less Concentrated In Human Brain Than Rat

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Arena Pharmaceuticals Inc. (ARNA) and Eisai Co. (ESALY, 4523.TO) said that a study of the diet pill lorcaserin showed that the drug seems to concentrate in the human brain less than it does in rats. The data is part of the companies' work to respond to Food and Drug Administration concerns that led to the pill being rejected for approval last year. The agency requested multiple sets of new data including studies related to breast cancer and brain cancer occurring in rats, and more information on heart-related risk. The company said that the effort to address other FDA concerns is ongoing. Arena conducted the study by measuring lorcaserin concentrations in human cerebrospinal fluid and then seeing how that compared to the amount of the drug in blood plasma. The company used an "apparent consistent relationship" of the amount of lorcaserin in the brain in relation to the spinal fluid of mice, rats and monkeys. That ratio was used to predict the corresponding amount of the drug in the human brain using the spinal fluid measurements. Using the new data and previous information, Arena estimates that human brain exposure to the drug is 1.7 times the plasma concentration at normal dose. In rats with a much higher dose, but which didn't have brain cancer, the ratio was 24 times. Arena noted that its estimates in the study are based on "certain assumptions and extrapolations" and the FDA may have different findings when looking at the raw data. The agency also may not view the company estimates as "reliable or predictive of the safety margin," Arena said in a statement. -By Thomas Gryta, Dow Jones Newswires; 212-416-2169;

Stock News for Arena (ARNA)
05/09/201617:50:49Quarterly Report (10-q)
05/09/201617:27:55Additional Proxy Soliciting Materials (definitive) (defa14a)
05/09/201617:14:44Current Report Filing (8-k)
05/09/201617:05:36Current Report Filing (8-k)
05/09/201616:05:00Arena Pharmaceuticals Reports First Quarter 2016 Financial Results...
05/09/201616:05:00Arena Pharmaceuticals Announces Appointment of Amit D. Munshi...
05/02/201616:05:00Arena Pharmaceuticals to Host First Quarter 2016 Financial Results...
04/28/201616:40:13Additional Proxy Soliciting Materials (definitive) (defa14a)
04/28/201616:22:41Proxy Statement (definitive) (def 14a)
04/12/201613:33:22Current Report Filing (8-k)
04/12/201608:00:00Arena Pharmaceuticals Reports Favorable Results from Phase 1b...
03/21/201606:07:19Current Report Filing (8-k)
03/04/201618:21:25Statement of Changes in Beneficial Ownership (4)
03/04/201618:19:54Statement of Changes in Beneficial Ownership (4)
03/04/201618:19:23Statement of Changes in Beneficial Ownership (4)
03/04/201618:17:39Statement of Changes in Beneficial Ownership (4)
03/04/201618:15:47Statement of Changes in Beneficial Ownership (4)
03/04/201618:14:18Statement of Changes in Beneficial Ownership (4)
02/29/201617:21:52Current Report Filing (8-k)
02/29/201616:00:00Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015...

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations